Cancer Biotherapy and Radiopharmaceuticals · 2008 · 24 citations · 18 references
MedicineOncologyPharmacotherapyBone ScintigraphyChemotherapyMetastasisBone MetastasisBone Metastasis PalliationGenitourinary Cancer PharmacotherapyMetastatic Bone DiseaseMetastatic Disease TreatmentProstate CancerBone Metastases ManagementBone Metastasis TherapyBone Pain PalliationChemotherapy For Prostate CancerMetastatic Bone Disease ManagementMetastatic Disease PalliationPain Score ReductionProstate Cancer Hormone Therapy
PURPOSE: 153Sm-lexidronam has been used for the palliation of symptoms from painful bone metastases for years, while docetaxel has recently been shown to improve the survival of patients with hormone-refractory prostate cancer (HRPC). The first clinical experience with the combination of both treatment modalities is reported. METHODS: Between 2005 and 2006, 12 patients with muliple bone metastases from HRPC were treated with a single application of 37 MBq/kg body weight 153Sm-lexidronam and 6 weekly infusions of 35 mg/m2 docetaxel. Data on survival, prostate-specific antigen (PSA) response, symptom palliation, toxicity, and scintigraphic follow-up are provided. RESULTS: Mean follow-up was 11.4 (range, 1.1-25.8) months, overall 1-year survival was 48.6%, and median survival was 11.5 months. A PSA response of >50% was documented in 50% of patients. The average pain score (visual analog scale: 1-10) was reduced from 5.1 to 1.4 (p = 0.016) with decrease of > or =2 in 58.3% of patients. The average World Health Organization medication level dropped from 1.6 to 1.1 (p = 0.5). Overall toxicity was moderate, but 1 patient died due to neutropenic sepsis. CONCLUSIONS: Our analysis demonstrates feasibility and therapeutic potential for the combination treatment and merits prospective investigation. Further studies will be planned with respect to the potentially synergistic hematologic toxicity of bone-seeking radiopharmaceuticals and chemotherapy.
18
F. Saad, D. M. Gleason, R. Murray et al. · JNCI Journal of the National Cancer Institute · 2004 · 1.2K citations
Glenn J. Bubley, Michael A. Carducci, William L. Dahut et al. · Journal of Clinical Oncology · 1999 · 984 citations
Arthur T. Porter, Alexander McEwan, John Powe et al. · International Journal of Radiation Oncology*Biology*Physics · 1993 · 532 citations